Artículos por temáticas

Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer's disease and Parkinson's disease: Therapeutic avenue of Dual OXR Antagonist (DORA)

Panda SP, Sinha S, Kesharwani A, Kumar S, Singh M, Kondepudi GM, Samuel A, Sanghi AK, Thapliyal S, Chaubey KK, Guru A.

Biochem Pharmacol. 2025 Mar;233:116794. doi: 10.1016/j.bcp.2025.116794. Epub 2025 Feb 5.

Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer's disease, vascular dementia, and other dementia types among patients with type 2 diabetes

Sun M, Wang X, Lu Z, Yang Y, Lv S, Miao M, Chen WM, Wu SY, Zhang J.

Diabetes Metab. 2025 Mar;51(2):101623. doi: 10.1016/j.diabet.2025.101623. Epub 2025 Feb 12.

Identification of potential therapeutic targets for Alzheimer's disease from the proteomes of plasma and cerebrospinal fluid in a multicenter Mendelian randomization study

Wang S, Xi J, Zhang M, Wang J.

Int J Biol Macromol. 2025 Mar;294:139394. doi: 10.1016/j.ijbiomac.2024.139394. Epub 2025 Jan 3.

Effect of a single nonpharmacological intervention on cognitive functioning in older adults with mild-to-moderate Alzheimer's disease: A meta-analysis of randomized controlled trials

Chen K, Zhao X, Zhou J.

J Prev Alzheimers Dis. 2025 Mar;12(3):100050. doi: 10.1016/j.tjpad.2024.100050. Epub 2025 Jan 1.

Identification and development of cGAS inhibitors and their uses to treat Alzheimer's disease

Alarcón-Espósito J, Nagiri RK, Gan L, Sinha SC.

Neurotherapeutics. 2025 Apr;22(3):e00536. doi: 10.1016/j.neurot.2025.e00536. Epub 2025 Jan 31.

Brexpiprazole: A Balance of Risks and Benefits

Hitt EM.

Sr Care Pharm. 2025 Mar 1;40(3):115-122. doi: 10.4140/TCP.n.2025.115.

Insulin resistance in Alzheimer's disease: signalling mechanisms and therapeutics strategies

Dahiya M, Yadav M, Goyal C, Kumar A.

Inflammopharmacology. 2025 Apr;33(4):1817-1831. doi: 10.1007/s10787-025-01704-2. Epub 2025 Mar 10.

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer's disease

Ketron GL, Grun F, Grill JD, Feldman HH, Rissman RA, Brewer GJ.

Alzheimers Res Ther. 2025 Mar 11;17(1):59. doi: 10.1186/s13195-025-01693-y.

Bioactive compounds and dietary patterns in Alzheimer's disease

Christimann G, Rocha G, Sattler JAG.

J Alzheimers Dis. 2025 Apr;104(3):597-610. doi: 10.1177/13872877251319048. Epub 2025 Feb 26.

NLRP3 inflammasome in Alzheimer's disease: molecular mechanisms and emerging therapies

Li Z, Gong C.

Front Immunol. 2025 Apr 7;16:1583886. doi: 10.3389/fimmu.2025.1583886. eCollection 2025.

Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease

Ruthirakuhan M, Guan DX, Mortby M, Gatchel J, Babulal GM.

Alzheimers Dement. 2025 Mar;21(3):e70079. doi: 10.1002/alz.70079.

The role of exosomes in diagnosis, pathophysiology, and management of Alzheimer's Disease

Daksh R, Mathew MS, Bosco AM, Sojan C, Tom AA, Bojja SL, Nampoothiri M.

Biochem Biophys Res Commun. 2025 Mar 25;754:151526. doi: 10.1016/j.bbrc.2025.151526. Epub 2025 Feb 21.

Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?

Azarfar K, Decourt B, Sanchez Camacho B, Lawrence JJ, Omondi TR, Sabbagh MN.

Expert Rev Neurother. 2025 May;25(5):521-535. doi: 10.1080/14737175.2025.2483928. Epub 2025 Apr 3.

Association Between the Gut Microbiota and Alzheimer's Disease: An Update on Signaling Pathways and Translational Therapeutics

Kulkarni R, Kumari S, Dhapola R, Sharma P, Singh SK, Medhi B, HariKrishnaReddy D.

Mol Neurobiol. 2025 Apr;62(4):4499-4519. doi: 10.1007/s12035-024-04545-2. Epub 2024 Oct 26.

Biological Effects of Dietary Restriction on Alzheimer's Disease: Experimental and Clinical Investigations

Liu Z, Zhang J, Jiang F, Liu C, Shao Y, Le W.

CNS Neurosci Ther. 2025 Apr;31(4):e70392. doi: 10.1111/cns.70392.